From Bench to Bedside in Diabetes: Why So Few Discoveries Reach a Patient

Most diabetes discoveries never reach a patient. A gene that looks promising in a Petri dish, a receptor that behaves oddly in a mouse, a statistical signal in a genome-wide association study: the great majority never become a pill, an injection, or a change in how a clinic works. The few that do can take fifteen to twenty years. Understanding why that journey is so long tells you a lot about how modern medicine actually advances.

The shorthand is "bench to bedside." The bench is the lab; the bedside is the patient. Translational medicine is the discipline of getting from one to the other, and it is less a straight line than an obstacle course with a high failure rate at every gate.

The stages, and where things die

It usually starts with biology. Suppose researchers notice that a receptor is overexpressed in the insulin-producing beta cells of people with type 2 diabetes, and that this seems to blunt insulin release. That is a mechanistic finding, interesting because it suggests a lever: dial the receptor down, and maybe you restore some insulin secretion. I worked on exactly this kind of question early in my career, as a co-author on a Science paper showing that overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. Finding the lever is the beginning, not the end.

From there the work moves into preclinical development: cell models, then animal models, then toxicology. Each step asks a harder question. Does the effect hold in a living system? Is the compound safe at a dose that does anything useful? Most candidates fail here, and that is the system working. Better to lose a molecule in a mouse than in a person.

If a candidate survives, it enters human trials, which run in phases. Phase 1 tests safety in a small group. Phase 2 looks for early signs the treatment works and refines the dose. Phase 3 is the large, expensive, multi-site trial that compares the new treatment against the current standard of care in hundreds or thousands of patients. This is where many promising drugs collapse, because a treatment can be safe and biologically elegant and still fail to beat what doctors already use.

Only after that comes regulatory review, where agencies such as the FDA or the European authorities decide whether the evidence justifies approval. And approval is not the finish line. A treatment that exists is not the same as a treatment a patient receives. That last gap, from approved therapy to real clinical use, is its own translation problem.

Why the attrition is so steep

The numbers are sobering. Across therapeutic areas, only a small fraction of compounds that enter human testing ever reach market, and the failure rate in metabolic disease has historically been high. Diabetes is biologically messy. It is not one disease but a cluster of conditions with overlapping symptoms and different underlying causes, which is part of why ethnic and individual differences in insulin sensitivity matter so much. I co-authored a meta-analysis in Diabetes Care on ethnic differences in the relationship between insulin sensitivity and insulin response, a paper since widely cited.

Heterogeneity is the enemy of a clean trial. If a drug helps one subgroup and does nothing for another, a study that lumps everyone together can show a flat, unconvincing average and the whole program dies. This is the core argument for precision medicine: match the right intervention to the right patient, rather than testing one-size-fits-all therapies on populations that are anything but uniform.

There is also the operational side. Recruiting patients, running trials across many clinics, and meeting modern device and software regulations all take years and money. Having sat on the industry side of this, as an International Medical Manager in global development at Novo Nordisk, where I helped lead clinical programs for GLP-1, insulin, and combination therapies, I can say the bottleneck is rarely a shortage of clever ideas. It is the long, unglamorous work of proving that an idea is safe, effective, and better, to a standard that holds up under scrutiny.

The last mile is also research

The part people forget is the bedside itself. An approved guideline that clinicians cannot easily apply during a seven-minute appointment changes very little. This is why I became interested in clinical decision support: tools that put validated evidence in front of a clinician at the moment of the decision. As co-developer and Head of Medical and Science on the team behind EASY Diabetes, I helped build an AI-based decision-support system for type 2 diabetes and tested it the way you would test a drug. A registered randomized controlled trial (EASY-1, NCT03258268) evaluated the system against standard of care. The system later received Sweden's Medtech4Health Innovation Award. Getting evidence into routine practice is a translational problem in its own right, and it deserves the same rigor as the lab work before it.

That is the honest shape of bench to bedside. Not a relay handoff but a gauntlet, where biology, trial design, regulation, and clinical reality each get a veto. The discoveries that survive are not always the most striking ones. They are the ones that keep clearing the next gate.

This article is educational and is not medical advice. For questions about your own diabetes care, talk to a qualified clinician who knows your history.